These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 23291982)

  • 1. Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells.
    Pires MM; Hopkins BD; Saal LH; Parsons RE
    Cancer Biol Ther; 2013 Mar; 14(3):246-53. PubMed ID: 23291982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multi-hit hypothesis in basal-like breast cancer.
    Dent P
    Cancer Biol Ther; 2013 Sep; 14(9):778-9. PubMed ID: 23974512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
    Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
    Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models.
    Melchor L; Molyneux G; Mackay A; Magnay FA; Atienza M; Kendrick H; Nava-Rodrigues D; López-García MÁ; Milanezi F; Greenow K; Robertson D; Palacios J; Reis-Filho JS; Smalley MJ
    J Pathol; 2014 Jun; 233(2):124-37. PubMed ID: 24615332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6.
    Wendt MK; Williams WK; Pascuzzi PE; Balanis NG; Schiemann BJ; Carlin CR; Schiemann WP
    Neoplasia; 2015 Jan; 17(1):124-33. PubMed ID: 25622905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
    Kim JS; Lee C; Bonifant CL; Ressom H; Waldman T
    Mol Cell Biol; 2007 Jan; 27(2):662-77. PubMed ID: 17060456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model.
    Kim G; Ouzounova M; Quraishi AA; Davis A; Tawakkol N; Clouthier SG; Malik F; Paulson AK; D'Angelo RC; Korkaya S; Baker TL; Esen ES; Prat A; Liu S; Kleer CG; Thomas DG; Wicha MS; Korkaya H
    Oncogene; 2015 Feb; 34(6):671-80. PubMed ID: 24531711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal PTEN determines mammary epithelial response to radiotherapy.
    Sizemore GM; Balakrishnan S; Thies KA; Hammer AM; Sizemore ST; Trimboli AJ; Cuitiño MC; Steck SA; Tozbikian G; Kladney RD; Shinde N; Das M; Park D; Majumder S; Krishnan S; Yu L; Fernandez SA; Chakravarti A; Shields PG; White JR; Yee LD; Rosol TJ; Ludwig T; Park M; Leone G; Ostrowski MC
    Nat Commun; 2018 Jul; 9(1):2783. PubMed ID: 30018330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway.
    Wan W; Hou Y; Wang K; Cheng Y; Pu X; Ye X
    Cell Death Dis; 2019 Mar; 10(3):248. PubMed ID: 30867411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
    Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
    Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
    She QB; Gruvberger-Saal SK; Maurer M; Chen Y; Jumppanen M; Su T; Dendy M; Lau YK; Memeo L; Horlings HM; van de Vijver MJ; Isola J; Hibshoosh H; Rosen N; Parsons R; Saal LH
    BMC Cancer; 2016 Aug; 16():587. PubMed ID: 27484095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and 
the correlation among them].
    Li X; Wang Q; Fu L; Liu M; Yu X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 40(9):973-8. PubMed ID: 26408616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway.
    Martinez JD; Mo Q; Xu Y; Qin L; Li Y; Xu J
    Int J Biol Sci; 2022; 18(1):229-241. PubMed ID: 34975329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors.
    Lobba ARM; Carreira ACO; Cerqueira OLD; Fujita A; DeOcesano-Pereira C; Osorio CAB; Soares FA; Rameshwar P; Sogayar MC
    PLoS One; 2018; 13(6):e0199254. PubMed ID: 29949609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olig1/2-Expressing Intermediate Lineage Progenitors Are Predisposed to PTEN/p53-Loss-Induced Gliomagenesis and Harbor Specific Therapeutic Vulnerabilities.
    Verma R; Chen X; Xin D; Luo Z; Ogurek S; Xin M; Rao R; Berry K; Lu QR
    Cancer Res; 2023 Mar; 83(6):890-905. PubMed ID: 36634201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin and erlotinib synergize to inhibit basal breast cancer.
    Lau YK; Du X; Rayannavar V; Hopkins B; Shaw J; Bessler E; Thomas T; Pires MM; Keniry M; Parsons RE; Cremers S; Szabolcs M; Maurer MA
    Oncotarget; 2014 Nov; 5(21):10503-17. PubMed ID: 25361177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
    Liu JC; Voisin V; Wang S; Wang DY; Jones RA; Datti A; Uehling D; Al-awar R; Egan SE; Bader GD; Tsao M; Mak TW; Zacksenhaus E
    EMBO Mol Med; 2014 Dec; 6(12):1542-60. PubMed ID: 25330770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.